Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) was down 4% on Thursday . The company traded as low as $66.06 and last traded at $66.52. Approximately 14,025 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 27,381 shares. The stock had previously closed at $69.30.
Analyst Ratings Changes
Several equities analysts recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective on shares of Korro Bio in a research note on Wednesday, March 27th. BMO Capital Markets reiterated an “outperform” rating and issued a $120.00 price objective on shares of Korro Bio in a research note on Tuesday, March 26th. Royal Bank of Canada upped their price objective on Korro Bio from $70.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, March 27th. Finally, HC Wainwright upped their price objective on Korro Bio from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, March 28th.
Get Our Latest Stock Report on KRRO
Korro Bio Trading Down 9.1 %
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Atlas Venture Life Science Advisors LLC bought a new position in shares of Korro Bio in the fourth quarter worth $53,648,000. Eventide Asset Management LLC bought a new position in shares of Korro Bio in the fourth quarter worth $26,185,000. 72 Investment Holdings LLC bought a new position in Korro Bio in the fourth quarter valued at $13,269,000. Vanguard Group Inc. bought a new position in Korro Bio in the fourth quarter valued at $12,988,000. Finally, Point72 Asset Management L.P. bought a new position in Korro Bio in the fourth quarter valued at $12,741,000. Institutional investors own 13.18% of the company’s stock.
About Korro Bio
Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.
Read More
- Five stocks we like better than Korro Bio
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Comprehensive PepsiCo Stock Analysis
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What Are the FAANG Stocks and Are They Good Investments?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.